Coronary microvascular dysfunction (CMD) is defined as a clinical syndrome of angina pectoris, which refers to the presence of chest pain symptoms, ischemic changes in the electrocardiogram, but no significant obstructive stenosis seen on coronary angiography.
Conditions
Interventions
Test group:Immediate use of a wide chest aerosol, sublingual administration3 sprays.
Control Group:Placebo
Single arm study:Wide chest aerosol, sublingual, 2 sprays, 3 times daily for 1 month.
Sponsors
Xuzhou Central Hospital
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Test 1: (1) Age 20-75 years old. (2) She had symptoms of chest tightness and pain, and had taken antiplatelet and statin drugs before admission. (3) Coronary artery stenosis = 50%; 2.Test 2: (1) Age 20-75 years old. (2) She had symptoms of chest tightness and pain, and had taken antiplatelet and statin drugs before admission. (3) Coronary artery stenosis = 1.2, or positive transmural ischemia, or positive cold compression test. (5) Echocardiography: LVEF>= 50%;
Exclusion criteria
Exclusion criteria: 1.Test 1: (1) Pregnant or lactating women. (2) Patients with prohibited and prudent use of nitrates, and patients with wide-chest aerosol and other aromatic warming drugs before operation. (3) Cognitive impairment, unable to cooperate. (4) serious damage to liver and kidney function and mental abnormalities. (5) Severe cardiopulmonary insufficiency, malignant arrhythmia. (6) Participants in other clinical trials. 2.Test two: (1) Pregnant or lactating women. (2) Nitrate esters are prohibited and used with caution. (3) Cognitive impairment, unable to cooperate. (4) serious damage to liver and kidney function and mental abnormalities. (5) Severe cardiopulmonary insufficiency, malignant arrhythmia. (6) Participants in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Test 2: TID ratio;Trial two: transmural ischemia;Test two: cold pressure test;Trial 1: QFR and IMRangio; | — |
Secondary
| Measure | Time frame |
|---|---|
| Trial 1: Changes in immediate heart rate and intracavitary blood pressure;Test 2: LVEF change (Exercise-Rest);Trial 2: PFR ratio (exercise/resting);Test 2: Blood routine, liver and kidney function; | — |
Countries
China
Contacts
Public ContactLiu He
Xuzhou Central Hospital
Outcome results
None listed